Thursday, October 15, 2026

Calix, Inc And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 15, 2020

Calix, Inc And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Mr. Cooper Group Inc.

89.8% sales growth and 28.09% return on equity

Mr. Cooper Group Inc. sales growth this year is anticipated to be 31% and 4% for next year.

Year-on-year quarterly revenue growth grew by 41.1%, now sitting on 2.52B for the twelve trailing months.

Mr. Cooper Group Inc.'s sales growth for the next quarter is 89.8%. The company's growth estimates for the present quarter and the next is 122.3% and 68.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.09%.

Mr. Cooper Group Inc.'s Stock Top and Bottom Yearly Value

Mr. Cooper Group Inc.'s stock is valued at $27.49 at 13:22 EST, below its 52-week high of $28.10 and way above its 52-week low of $4.31.

Mr. Cooper Group Inc.'s Moving Average

Mr. Cooper Group Inc.'s worth is way higher than its 50-day moving average of $24.98 and way above its 200-day moving average of $19.18.

2. Randgold

28.1% sales growth and 14.43% return on equity

Randgold sales growth this year is expected to be 28.7% and 7.1% for next year.

Year-on-year quarterly revenue growth grew by 32.2%, now sitting on 12.2B for the twelve trailing months.

Randgold's sales growth for the next quarter is 28.1%. The company's growth estimates for the ongoing quarter and the next is 105.9% and 131.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.43%.

Randgold's Stock Top and Bottom Yearly Value

Randgold's stock is valued at $22.77 at 13:22 EST, way under its 52-week high of $31.22 and way higher than its 52-week low of $12.65.

Randgold's Moving Average

Randgold's value is under its 50-day moving average of $25.05 and way below its 200-day moving average of $26.88.

3. StoneCo Ltd.

48.3% sales growth and 7.86% return on equity

StoneCo Ltd. sales growth this year is anticipated to be 36.7% and 52.4% for next year.

Year-on-year quarterly revenue growth grew by 55%, now sitting on N/A for the twelve trailing months.

StoneCo Ltd.'s sales growth for the next quarter is 48.3%. The company's growth estimates for the current quarter and the next is 38.9% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.86%.

StoneCo Ltd.'s Stock Top and Bottom Yearly Value

StoneCo Ltd.'s stock is valued at $74.26 at 13:22 EST, below its 52-week high of $74.93 and way higher than its 52-week low of $17.72.

StoneCo Ltd.'s Moving Average

StoneCo Ltd.'s worth is way higher than its 50-day moving average of $64.40 and way higher than its 200-day moving average of $50.73.

4. DAQO New Energy Corp.

42.4% sales growth and 12.84% return on equity

DAQO New Energy Corp. sales growth this year is anticipated to be 91% and 24.5% for next year.

Year-on-year quarterly revenue growth grew by 49.6%, now sitting on 546.8M for the twelve trailing months.

DAQO New Energy Corp.'s sales growth for the next quarter is 42.4%. The company's growth estimates for the ongoing quarter and the next is 226.5% and 75.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.84%.

DAQO New Energy Corp.'s Stock Top and Bottom Yearly Value

DAQO New Energy Corp.'s stock is valued at $42.22 at 13:22 EST, way below its 52-week high of $48.73 and way above its 52-week low of $8.32.

DAQO New Energy Corp.'s Moving Average

DAQO New Energy Corp.'s worth is higher than its 50-day moving average of $40.65 and way above its 200-day moving average of $26.59.

5. QCR Holdings, Inc.

10.6% sales growth and 10.66% return on equity

QCR Holdings, Inc. sales growth this year is expected to be 12.8% and 1% for next year.

Year-on-year quarterly revenue growth grew by 5.3%, now sitting on 208.6M for the twelve trailing months.

QCR Holdings, Inc.'s sales growth for the next quarter is 10.6%. The company's growth estimates for the present quarter and the next is a negative 8.9% and 27.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.66%.

QCR Holdings, Inc.'s Stock Top and Bottom Yearly Value

QCR Holdings, Inc.'s stock is valued at $39.06 at 13:22 EST, way under its 52-week high of $44.76 and way higher than its 52-week low of $22.39.

QCR Holdings, Inc.'s Moving Average

QCR Holdings, Inc.'s worth is higher than its 50-day moving average of $35.60 and way higher than its 200-day moving average of $31.28.

6. Molina Healthcare Inc

25.4% sales growth and 40.03% return on equity

Molina Healthcare Inc sales growth this year is expected to be 16.1% and 17.5% for next year.

Year-on-year quarterly revenue growth grew by 16%, now sitting on 17.66B for the twelve trailing months.

Molina Healthcare Inc's sales growth for the next quarter is 25.4%. The company's growth estimates for the present quarter and the next is a negative 45.4% and 23.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 40.03%.

Molina Healthcare Inc's Stock Top and Bottom Yearly Value

Molina Healthcare Inc's stock is valued at $200.24 at 13:22 EST, way below its 52-week high of $224.00 and way higher than its 52-week low of $102.85.

Molina Healthcare Inc's Moving Average

Molina Healthcare Inc's value is below its 50-day moving average of $208.96 and above its 200-day moving average of $189.77.

7. Calix, Inc

19.5% sales growth and 5.02% return on equity

Calix, Inc sales growth this year is anticipated to be 25.1% and 5.4% for next year.

Year-on-year quarterly revenue growth grew by 31.5%, now sitting on 491.4M for the twelve trailing months.

Calix, Inc's sales growth for the next quarter is 19.5%. The company's growth estimates for the ongoing quarter and the next is 266.7% and 325%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.02%.

Calix, Inc's Stock Top and Bottom Yearly Value

Calix, Inc's stock is valued at $23.83 at 13:22 EST, way below its 52-week high of $27.78 and way higher than its 52-week low of $5.61.

Calix, Inc's Moving Average

Calix, Inc's worth is under its 50-day moving average of $24.30 and way above its 200-day moving average of $19.43.

8. BioLife Solutions, Inc.

29.5% sales growth and 5.9% return on equity

BioLife Solutions, Inc. sales growth this year is expected to be 71.2% and 48.2% for next year.

Year-on-year quarterly revenue growth grew by 70.8%, now sitting on 41.66M for the twelve trailing months.

BioLife Solutions, Inc.'s sales growth for the next quarter is 29.5%. The company's growth estimates for the ongoing quarter and the next is a negative 200% and negative -100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.9%.

BioLife Solutions, Inc.'s Stock Top and Bottom Yearly Value

BioLife Solutions, Inc.'s stock is valued at $40.58 at 13:22 EST, under its 52-week high of $41.39 and way higher than its 52-week low of $7.37.

BioLife Solutions, Inc.'s Moving Average

BioLife Solutions, Inc.'s value is way higher than its 50-day moving average of $33.43 and way above its 200-day moving average of $24.32.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com